Division of Gastroenterology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea.
Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Republic of Korea.
Surg Today. 2021 Jun;51(6):978-985. doi: 10.1007/s00595-020-02188-z. Epub 2021 Jan 2.
The C-reactive protein (CRP)/albumin ratio has been identified as a potential prognostic factor for several malignancies. We, therefore, assessed the prognostic role of the CRP/albumin ratio in resected extrahepatic cholangiocarcinoma (EC).
A total of 235 patients were retrospectively analyzed between March 2005 and December 2017. The correlations among the preoperative CRP/albumin ratio, clinicopathological factors, and clinical outcomes were investigated.
There were 143 males (60.8%), and the median age at the diagnosis was 70.1 (range 41.0-85.5) years. Patients were diagnosed with perihilar bile duct cancer (n = 61) and distal bile duct cancer (n = 174). The median recurrence-free survival and overall survival were 32.7 and 38.7 months, respectively. The optimal prognostic cut-off point of the CRP/albumin ratio for the survival was 0.18 (× 10). According to the Kaplan-Meier analysis with a log-rank test, the high CRP/albumin ratio group (≥ 0.18) had a significantly shorter overall survival than the low CRP/albumin ratio group (< 0.18) (29.8 vs. 54.6 months, p = 0.002). A multivariate logistic regression analysis for the overall survival showed that CA19-9 ≥ 37 and a high CRP/albumin ratio were associated with a shorter overall survival.
A high CRP/albumin ratio appears to be significantly associated with clinically worse outcomes in patients with resected EC.
C 反应蛋白(CRP)/白蛋白比值已被确定为多种恶性肿瘤的潜在预后因素。因此,我们评估了 CRP/白蛋白比值在切除性肝外胆管癌(EC)中的预后作用。
回顾性分析了 2005 年 3 月至 2017 年 12 月期间的 235 例患者。研究了术前 CRP/白蛋白比值与临床病理因素及临床结局之间的相关性。
男性 143 例(60.8%),诊断时的中位年龄为 70.1 岁(范围 41.0-85.5)。患者被诊断为肝门部胆管癌(n=61)和远端胆管癌(n=174)。中位无复发生存期和总生存期分别为 32.7 和 38.7 个月。CRP/白蛋白比值的最佳预后截断点为 0.18(×10)。根据 Kaplan-Meier 分析和对数秩检验,CRP/白蛋白比值高(≥0.18)组的总生存期明显短于 CRP/白蛋白比值低(<0.18)组(29.8 vs. 54.6 个月,p=0.002)。多变量 logistic 回归分析总生存期显示,CA19-9≥37 和 CRP/白蛋白比值高与总生存期较短相关。
CRP/白蛋白比值升高与切除性 EC 患者的临床结局较差显著相关。